» Articles » PMID: 32618445

Monogenetic Causes of Chilblains, Panniculitis and Vasculopathy: the Type I Interferonopathies

Overview
Date 2020 Jul 4
PMID 32618445
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Type I interferonopathies are a clinically heterogeneous group of inherited disorders of the innate immune system characterized by constitutive activation of the type I interferon signaling pathway. Cutaneous vasculopathy, lipodystrophy, interstitial lung disease and brain calcifications are the typical manifestations characterizing affected patients. The pathogenic mechanism commonly underlying these disorders is the abnormal activation of immune pathways involved in recognition of non-self-oligonucleotides. These natural defenses against virus consent humans to survive the infections. Target therapies capable of inhibiting type I interferon signaling pathway seem effective in these patients, albeit with possible incomplete responses and severe side effects.

Citing Articles

Chilblains observed during the COVID-19 pandemic cannot be distinguished from classic, cold-related chilblains.

De Greef A, Choteau M, Herman A, Bouzin C, Marot L, Dachelet C Eur J Dermatol. 2022; 32(3):377-383.

PMID: 36065533 PMC: 9660172. DOI: 10.1684/ejd.2022.4260.


Pandemic chilblains: Are they SARS-CoV-2-related or not?.

De Greef A, Coulie P, Baeck M Clin Immunol. 2022; 237:108984.

PMID: 35338000 PMC: 8942450. DOI: 10.1016/j.clim.2022.108984.


Clinical Patterns and Morphology of COVID-19 Dermatology.

Agnihothri R, Fox L Dermatol Clin. 2021; 39(4):487-503.

PMID: 34556240 PMC: 8165088. DOI: 10.1016/j.det.2021.05.006.


Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic.

Schvartz A, Belot A, Kone-Paut I Front Pediatr. 2020; 8:605807.

PMID: 33344389 PMC: 7746854. DOI: 10.3389/fped.2020.605807.